PMID- 33578735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 4
DP  - 2021 Feb 10
TI  - Tackling HLA Deficiencies Head on with Oncolytic Viruses.
LID - 10.3390/cancers13040719 [doi]
LID - 719
AB  - Dysregulation of HLA (human leukocyte antigen) function is increasingly 
      recognized as a common escape mechanism for cancers subject to the pressures 
      exerted by immunosurveillance or immunotherapeutic interventions. Oncolytic 
      viruses have the potential to counter this resistance by upregulating HLA 
      expression or encouraging an HLA-independent immunological responses. However, to 
      achieve the best therapeutic outcomes, a prospective understanding of the HLA 
      phenotype of cancer patients is required to match them to the characteristics of 
      different oncolytic strategies. Here, we consider the spectrum of immune 
      competence observed in clinical disease and discuss how it can be best addressed 
      using this novel and powerful treatment approach.
FAU - Fisher, Kerry
AU  - Fisher K
AUID- ORCID: 0000-0001-9521-2134
AD  - Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
FAU - Hazini, Ahmet
AU  - Hazini A
AD  - Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
FAU - Seymour, Leonard W
AU  - Seymour LW
AUID- ORCID: 0000-0003-3825-0841
AD  - Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
LA  - eng
GR  - 29106/CRUK_/Cancer Research UK/United Kingdom
GR  - C552/A29106/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20210210
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7916504
OTO - NOTNLM
OT  - class I HLA
OT  - immunosurveillance
OT  - immunotherapy
OT  - oncolytic virus
COIS- L.W.S. and K.F. own equity in Psioxus Therapeutics and Theolytics Ltd.; K.F. is 
      an employee of Theolytics and L.W.S. consults for both companies. The funders had 
      no role in the design of the study; in the collection, analyses, or 
      interpretation of data; in the writing of the manuscript; or in the decision to 
      publish the results.
EDAT- 2021/02/14 06:00
MHDA- 2021/02/14 06:01
PMCR- 2021/02/10
CRDT- 2021/02/13 01:01
PHST- 2020/12/12 00:00 [received]
PHST- 2021/01/27 00:00 [revised]
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/02/13 01:01 [entrez]
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/02/14 06:01 [medline]
PHST- 2021/02/10 00:00 [pmc-release]
AID - cancers13040719 [pii]
AID - cancers-13-00719 [pii]
AID - 10.3390/cancers13040719 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Feb 10;13(4):719. doi: 10.3390/cancers13040719.